```
Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2          "Ask CAS" for self-help around the clock
 NEWS  3  FEB 27  New STN AnaVist pricing effective March 1, 2006
 NEWS  4  APR 04  STN AnaVist $500 visualization usage credit offered
 NEWS  5  MAY 10  CA/CAplus enhanced with 1900-1906 U.S. patent records
 NEWS  6  MAY 11  KOREAPAT updates resume
 NEWS  7  MAY 19  Derwent World Patents Index to be reloaded and enhanced
 NEWS  8  MAY 30  IPC 8 Rolled-up Core codes added to CA/CAplus and
                  USPATFULL/USPAT2
 NEWS  9  MAY 30  The F-Term thesaurus is now available in CA/CAplus
 NEWS 10  JUN 02  The first reclassification of IPC codes now complete in
                  INPADOC
 NEWS 11  JUN 26  TULSA/TULSA2 reloaded and enhanced with new search and
                  and display fields
 NEWS 12  JUN 28  Price changes in full-text patent databases EPFULL and PCTFULL

 NEWS EXPRESS  JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT
               MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
               AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.

 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8
 NEWS X25      X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  **************************************************************
  *   Due to scheduled maintenance of STN on Sunday, July 9, 2006,   *
  *   some databases may not be available until 04:00 (4:00 AM)      *
  *   Eastern Daylight Time.                                         *
  **************************************************************

* * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:42:15 ON 06 JUL 2006

=> file reg
COST IN U.S. DOLLARS                              SINCE FILE     TOTAL
                                                       ENTRY   SESSION
```

FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 14:42:35 ON 06 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 JUL 2006 HIGHEST RN 890705-10-9
DICTIONARY FILE UPDATES: 5 JUL 2006 HIGHEST RN 890705-10-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10507006c.str





chain nodes :
11 17 18 21
ring nodes :
1 2 3 4 5 6 7 8 9 10 19 20
chain bonds :
2-21 5-11 10-17 10-18
ring bonds :
1-2 1-20 2-3 3-4 3-5 4-7 4-19 5-6 6-7 6-8 7-10 8-9 9-10 19-20
exact/norm bonds :
1-2 1-20 2-3 2-21 3-4 3-5 4-7 4-19 5-6 5-11 6-7 6-8 7-10 8-9 9-10
10-17 10-18 19-20

G1:C,N

G2:C,O,S,N

G3:Cy,Ak

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:CLASS 17:CLASS 18:CLASS 19:Atom 20:Atom 21:CLASS

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 C,N

G2 C,O,S,N

G3 Cy,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:43:23 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 347204 TO ITERATE

100.0% PROCESSED 347204 ITERATIONS 432 ANSWERS
SEARCH TIME: 00.00.05

L2 432 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 167.38 167.59

FILE 'CAPLUS' ENTERED AT 14:43:35 ON 06 JUL 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 6 Jul 2006 VOL 145 ISS 2
FILE LAST UPDATED: 5 Jul 2006 (20060705/ED)

=> s l2 full
L3 10 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:714220 CAPLUS
DOCUMENT NUMBER: 143:326265
TITLE: Novel approach to isoindolo[2,1-a]quinolines: Synthesis of 1- and 3-halo-substituted 11-oxo-5,6,6a,11-tetrahydroisoindolo[2,1-a]quinoline-10-carboxylic acids
AUTHOR(S): Boltukhina, Ekaterina V.; Zubkov, Fedor I.; Nikitina, Eugenia V.; Varlamov, Alexey V.
CORPORATE SOURCE: Organic Chemistry Department of Russian People's Friendship University, Moscow, 117198, Russia
SOURCE: Synthesis (2005), (11), 1859-1875
CODEN: SYNTBF; ISSN: 0039-7881
PUBLISHER: Georg Thieme Verlag
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:326265
AB A series of 1- and 3-halo-substituted isoindolo[2,1-a]quinolines were obtained by electrophilic cyclization of methallyl- and allyl-substituted isoindolo-7-carboxylic acids. The influence of halogen atoms on the stereochem. of the formation of key intermediates, 3a,6-epoxyisoindoles, was studied.
IT 432000-16-3P 445265-31-6P 496018-44-1P
496018-48-5P 672275-13-7P 865353-92-0P
865353-93-1P 865353-94-2P 865353-95-3P
865353-96-4P 865353-97-5P 865353-98-6P
865353-99-7P 865354-01-4P 865354-02-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of oxotetrahydroisoindoloquinolinecarboxylates by electrophilic cyclization of methallyl- and allylisoindolocarboxylates)
RN 432000-16-3 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-fluoro-5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 445265-31-6 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 496018-44-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-fluoro-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 496018-48-5 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-chloro-5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 672275-13-7 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 1-chloro-5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-92-0 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-chloro-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-93-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-bromo-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-94-2 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 1-chloro-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-95-3 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 1-bromo-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-96-4 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1-iodo-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-97-5 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-bromo-5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-98-6 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 1-bromo-5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865353-99-7 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 1-fluoro-5,6,6a,11-tetrahydro-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865354-01-4 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-3-iodo-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 865354-02-5 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-3-iodo-5-methyl-11-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:496436 CAPLUS
DOCUMENT NUMBER: 144:170907
TITLE: Study of regioselectivity of intramolecular cyclization of N-(m-R-phenyl)- and N-(α-naphthyl)-2-allyl(methallyl)-6-carboxy-4-oxo-3-aza-10-oxatricyclo[5.2.1.01,5]dec-8-enes
AUTHOR(S): Zubkov, F. I.; Boltukhina, E. V.; Nikitina, E. V.; Varlamov, A. V.
CORPORATE SOURCE: Peoples' Friendship University of Russia, Moscow, 117198, Russia
SOURCE: Russian Chemical Bulletin (2005), Volume Date 2004, 53(12), 2816-2829
CODEN: RCBUEY; ISSN: 1066-5285
PUBLISHER: Springer Science+Business Media, Inc.
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Regioselectivity of the intramol. electrophilic substitution in a series of N-(meta-substituted-phenyl)- and N-(α-naphthyl)-2-allyl(methallyl)-6-carboxy-4-oxo-3-aza-10-oxatricyclo[5.2.1.01,5]dec-8-enes in reactions with phosphoric acid was studied. The reactions of the N-(meta-substituted-phenyl) derivs. proceed nonregioselectively to form mixts. of 2- and 4-substituted isoindolo[2,1-a]quinolines, whereas the reactions of the N-(α-naphthyl) derivs. occur regioselectively at the β-position of the naphthyl fragment.
IT 723747-25-9P 874797-28-1P 874797-29-2P
874797-30-5P 874797-33-8P 874797-34-9P
874797-35-0P 874797-40-7P 874797-41-8P
874797-42-9P 874797-43-0P 874797-44-1P
874797-46-3P 874797-48-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselectivity of intramol. Diels-Alder reaction of N-arylallylcarboxyazaoxatricyclodecenones)
RN 723747-25-9 CAPLUS
CN Benz[h]isoindolo[2,1-a]quinoline-12-carboxylic acid, 7,8,8a,13-tetrahydro-7,7-dimethyl-13-oxo- (9CI) (CA INDEX NAME)



RN 874797-28-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-2,5,5-trimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 874797-29-2 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-2-methoxy-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 874797-30-5 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 4-chloro-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 874797-33-8 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-2,5-dimethyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874797-34-9 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-2-methoxy-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874797-35-0 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 2-chloro-5,6,6a,11-tetrahydro-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874797-40-7 CAPLUS
CN Benz[h]isoindolo[2,1-a]quinoline-12-carboxylic acid, 7,8,8a,13-tetrahydro-7-methyl-13-oxo-, (7R,8aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874797-41-8 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 2-chloro-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 874797-42-9 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-4,5,5-trimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 874797-43-0 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-4-methoxy-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 874797-44-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-4,5-dimethyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874797-46-3 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-4-methoxy-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 874797-48-5 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 4-chloro-5,6,6a,11-tetrahydro-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 3 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:436085 CAPLUS
DOCUMENT NUMBER: 143:133316
TITLE: Hantzsch Synthesis of Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridines: Partial Agonists of the Calcitonin Receptor
AUTHOR(S): Boros, Eric E.; Cowan, David J.; Cox, Richard F.; Mebrahtu, Makda M.; Rabinowitz, Michael H.; Thompson, James B.; Wolfe, Lawrence A., III
CORPORATE SOURCE: GlaxoSmithKline Research and Development, Research Triangle Park, NC, 27709, USA
SOURCE: Journal of Organic Chemistry (2005), 70(13), 5331-5334
CODEN: JOCEAH; ISSN: 0022-3263

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB Small mol. calcitonin receptor agonists are of potential utility in the treatment and prevention of osteoporosis. 3-Amino-6,7-dihydro-1H,5H-pyrazolo[1,2-a]pyrazol-1-one (I) was a useful intermediate in the synthesis of pyrazolopyridine calcitonin receptor partial agonists II [R = 2-furylmethyl, 3-pyridylmethyl, 3-FC6H4CH2, 1-indanyl; X = O, S, CH:CH; Y = F, CF3]. The corresponding dihydropyridines were conveniently prepared by reaction of I with Knoevenagel adducts of 4-YC6H4CH2CH2COCH2CO2Et (III) or by a three component reaction with I, III, and 4-OCHC6H4CO2H. Oxidation to pyridine and amide formation afforded I.

IT 603998-39-6P 603998-40-9P 858671-18-8P
858671-19-9P 858671-20-2P 858671-21-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(Hantzsch synthesis of pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridines as partial agonists of the calcitonin receptor)

RN 603998-39-6 CAPLUS

CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 603998-40-9 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-4-[5-[[(2-furanylmethyl)amino]carbonyl]-2-thienyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 858671-18-8 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-4-[5-[[(3-pyridinylmethyl)amino]carbonyl]-2-thienyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 858671-19-9 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-4-[5-[[[(3-fluorophenyl)methyl]amino]carbonyl]-2-thienyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 858671-20-2 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-furanyl]-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 858671-21-3 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



IT 603999-11-7P 858671-15-5P 858671-16-6P
858671-17-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(Hantzsch synthesis of pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridines as partial agonists of the calcitonin receptor)

RN 603999-11-7 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-(4-carboxyphenyl)-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 858671-15-5 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-(5-carboxy-2-thienyl)-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 858671-16-6 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-(5-carboxy-2-furanyl)-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 858671-17-7 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-(4-carboxyphenyl)-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, 3-ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 4 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:348105 CAPLUS

DOCUMENT NUMBER: 143:26478

TITLE: New synthetic approach to substituted isoindolo[2,1-a]quinoline carboxylic acids via intramolecular Diels-Alder reaction of 4-(N-furyl-2)-4-arylaminobutenes-1 with maleic anhydride

AUTHOR(S): Zubkov, Fedor I.; Boltukhina, Ekaterina V.; Turchin, Konstantin F.; Borisov, Roman S.; Varlamov, Alexey V.

CORPORATE SOURCE: Organic Chemistry Department, Russian Peoples Friendship University, Moscow, 117198, Russia

SOURCE: Tetrahedron (2005), 61(16), 4099-4113
CODEN: TETRAB; ISSN: 0040-4020

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:26478

GI



I



II



III

AB Acylation of substituted 4-(2-furyl)-4-arylaminobut-1-enes I (R1 = H, Me; R2 = H, 2-Me, 4-MeO, etc.) with maleic anhydride provided 2-allyl-6-carboxy-4-oxo-3-aza-10-oxatricyclo[5.2.1.01.5]dec-8-enes II in high yields under mild reaction conditions. The Diels-Alder adducts II are formed via an initial amide formation followed by a stereoselective intramol. [4 + 2] exo-cycloaddn. reaction. Treatment of the tricyclic compds. II with phosphoric acid at high temps. (70-120 °C) promoted cyclic ether opening, intramol. cyclization and aromatization to give the corresponding tetracyclic compds., 5,6,6a,11-tetrahydro-10-carboxyisoindolo[2,1-a]quinolines III, in moderate yields. The influence of the acid and the reaction temperature on the cyclization reactions are also discussed.

IT 433974-44-8P 445265-33-8P 496018-43-0P
496018-45-2P 588706-12-1P 588706-13-2P
588706-15-4P 853064-11-6P 853064-12-7P
853064-13-8P 853064-14-9P 853064-15-0P
853064-16-1P 853064-17-2P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of tetrahydroisoindolo[2,1-a]quinolinecarboxylic acids via Diels-Alder cycloaddn. of (furyl)arylaminobutenes with maleic anhydride and ring opening - intramol. cyclization of azaoxatricyclodecenes)

RN 433974-44-8 CAPLUS

CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1-methoxy-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 445265-33-8 CAPLUS

CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-3,5,5-trimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 496018-43-0 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 496018-45-2 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1,3,5,5-tetramethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 588706-12-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1,5,5-trimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 588706-13-2 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 588706-15-4 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-3-methoxy-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 853064-11-6 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 1-ethyl-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 853064-12-7 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5,5-dimethyl-3-(1-methylethyl)-11-oxo- (9CI) (CA INDEX NAME)



RN 853064-13-8 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 853064-14-9 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1,5-dimethyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 853064-15-0 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1-methoxy-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 853064-16-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-3-methoxy-5-methyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 853064-17-2 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1,2,5-trimethyl-11-oxo-, (5R,6aR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:325697 CAPLUS
DOCUMENT NUMBER: 142:392438
TITLE: Preparation of pyrazino[2,1-a]isoindol-6(2H)-one derivatives and related compounds as modulators of serotonin receptors
INVENTOR(S): Wacker, Dean A.; Zhao, Guohua; Kwon, Chet; Varnes, Jeffrey G.; Stein, Philip D.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 109 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005080074	A1	20050414	US 2004-958325	20041005
WO 2005035533	A1	20050421	WO 2004-US32849	20041006
WO 2005035533	C1	20050630		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1675859	A1	20060705	EP 2004-794259	20041006
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.:

US 2003-509437P	P	20031007
US 2004-541746P	P	20040204
US 2004-958325	A	20041005
WO 2004-US32849	W	20041006

OTHER SOURCE(S): MARPAT 142:392438
GI



I

AB The title compds. (I) [A = CR1R2; B = CR4R5; D = CR6R7, CO or SO2; W = a direct bond, CR12R13, O, S, NR16, CO; X = CR14R15, CO, SO2; m, n = 1, ; R1, R2, R4, R5, R6, R7 = H, each (un)substituted C1-4 alkyl, C2-4 alkenyl, cycloalkyl, alkylaryl, alkylheteroaryl, aryl, or heteroaryl; R3 = H, C1-4 alkyl, cycloalkyl, alkylaryl, alkylheteroaryl, aryl, heteroaryl; R8-11 = H, hydroxy, alkyl, alkenyl, alkynyl, oxyalkyl, oxyalkenyl, oxyalkynyl, oxycycloalkyl, oxyperfluoroalkyl, OCF3, thioalkyl, thioalkenyl, thioalkynyl, thioaryl, thioheteroaryl, thiocycloalkyl, aryl, heteroaryl, heterocyclyl, nitrile, halogen, carboaminoalkyl, carboaminoalkenyl, carboaminoakynyl, carboaminoaryl, carboaminocycloalkyl, carboalkyl, carboalkenyl, carboalkynyl, carboaryl, carbocycloalkyl, carboheterocyclyl, carboheteroaryl, carboaminoheterocyclyl, carboaminoheteroaryl, aminocarboalkyl, aminocarboalkenyl, aminocarboalkynyl, etc.; or optionally R8 and R9, R9 and R10 or R10 and R11 may be taken together to form a cycloalkyl, heterocyclyl, aryl or heteroaryl; R12, R13 = H, C1-4 alkyl, hydroxy, oxyalkyl, cycloalkyl, aryl, heteroaryl; R14, R15 = H, C1-4 alkyl, cycloalkyl, aryl, alkylaryl; R16 = H, C1-4 alkyl, aryl, alkylaryl, carboaminoalkyl, carboaminoalkenyl, carboaminoakynyl, etc.; wherein R1 and R4 taken together can form a 5 or 6 membered ring] or stereoisomers or pharmaceutically acceptable salts thereof are prepared The present invention provides modulators of serotonin receptors, pharmaceutical compns. containing such modulators and methods for treating various diseases, conditions, and disorders associated with modulation of serotonin receptors such as, for example: metabolic diseases, which includes but is not limited to obesity, diabetes, diabetic complications, atherosclerosis, impaired glucose tolerance and dyslipidemia; central nervous system diseases which includes but is not limited to, anxiety, depression, obsessive compulsive disorder, panic disorder, psychosis, schizophrenia, sleep disorder, sexual disorder and social phobias; cephalic pain; migraine; and gastrointestinal disorders using such compds. and compns. Thus, chlorination of 2-trifluoromethoxybenzoic acid with oxalyl chloride in the presence of DMF in CH2Cl2 followed by amidation with diethylamine gave 94% N,N-diethyl-2-trifluoromethoxybenzamide which was treated with sec-butyllithium/hexane in the presence of N,N,N',N'-tetramethylethylenediamine in THF at -78° for 1 h and formylated by DMF for 1 h to give N,N-diethyl-2-formyl-6-trifluoromethoxybenzamide. Hydrolysis of N,N-diethyl-2-formyl-6-trifluoromethoxybenzamide with 6 M aqueous HCl at reflux gave 2-formyl-6-trifluoromethoxybenzoic acid which was cyclocondensed with 1-(Benzyloxycarbonylamino)-2-aminoethane hydrochloride and NaCN in the presence of AcONa in a mixture of AcOH and ethanol at room temperature overnight to give 2-[2-[(benzyloxycarbonyl)amino]ethyl]-1-cyano-1,3-dihydro-4-trifluoromethoxyisoindol-3(1H)-one (II). Hydrogenation of II over 10% Pd-C in a mixture of concentrated HCl and ethanol gave, after workup and radial chromatog., 1,3,4,10b-tetrahydro-7-trifluoromethoxypyrazino[2,1-a]isoindol-6(2H)-one.

IT 850033-28-2P, (±)-1,3,4,10b-Tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(intermediate; preparation of pyrazino[2,1-a]isoindolone derivs. and related compds. as serotonin receptor modulators for treating metabolic diseases, central nervous system diseases, gastrointestinal disorders, etc.)

RN 850033-28-2 CAPLUS

CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



IT 850033-36-2P 850033-38-4P 850033-65-7P
850033-77-1P 850033-88-4P 850034-22-9P,
2-(tert-Butoxycarbonyl)-(10bR)-1,3,4,10b-tetrahydro-9-cyano-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850034-24-1P,
2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-7-cyanopyrazino[2,1-a]isoindol-6(2H)-one 850034-27-4P 850034-39-8P
850034-48-9P 850034-49-0P 850034-72-9P
850034-75-2P 850034-78-5P 850034-84-3P,
2-(tert-Butoxycarbonyl)-(10bR)-1,3,4,10b-tetrahydro-9-(pentan-3-yl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850034-91-2P
850034-94-5P 850034-96-7P 850034-98-9P,
2-(tert-Butoxycarbonyl)-(10bR)-1,3,4,10b-tetrahydro-9-methoxy-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850035-05-1P
850035-33-5P 850035-39-1P, 2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-9-formyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850035-41-5P, 2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-9-difluoromethyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850036-37-2P, 2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-9-chloro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
850036-62-3P 850036-70-3P, 2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-10b-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyrazino[2,1-a]isoindolone derivs. and related compds. as serotonin receptor modulators for treating metabolic diseases, central nervous system diseases, gastrointestinal disorders, etc.)

RN 850033-36-2 CAPLUS

CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-bromo-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-38-4 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-[2-methyl-4-(trifluoromethoxy)phenyl]-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-65-7 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-(2-furanyl)-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-77-1 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-9-(phenylamino)-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-88-4 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-[4-(1-methylethoxy)-2-(trifluoromethyl)phenyl]-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-22-9 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-cyano-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-24-1 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 7-cyano-3,4,6,10b-tetrahydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850034-27-4 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-9-propyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-39-8 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-[(2-ethoxyphenyl)amino]-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-48-9 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-amino-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-49-0 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-[(2-ethoxy-3-pyridinyl)amino]-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-72-9 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-9-(1Z)-1-propenyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 850034-75-2 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(2-methylpropyl)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-78-5 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(methylthio)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-84-3 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-(1-ethylpropyl)-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-91-2 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(hydroxymethyl)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-94-5 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(methoxymethyl)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-96-7 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-hydroxy-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-98-9 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-methoxy-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-05-1 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-ethynyl-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-33-5 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(2-methylcyclopropyl)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-39-1 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-formyl-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850035-41-5 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-(difluoromethyl)-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850036-37-2 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-chloro-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850036-62-3 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 7-ethenyl-3,4,6,10b-tetrahydro-6-oxo-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850036-70-3 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-10b-methyl-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



IT 850033-29-3P 850033-30-6P 850033-31-7P,
(±)-1,3,4,10b-Tetrahydro-2-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850033-35-1P 850033-37-3P
850033-40-8P 850033-41-9P 850033-42-0P
850033-43-1P 850033-44-2P 850033-46-4P
850033-48-6P 850033-49-7P 850033-51-1P
850033-52-2P 850033-59-9P 850033-61-3P
850033-63-5P 850033-64-6P 850033-66-8P,
(±)-1,3,4,10b-Tetrahydro-3,3-dimethyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850033-69-1P, (3S,10BR)-1,3,4,10b-tetrahydro-3-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850033-70-4P, (3S,10BS)-1,3,4,10b-tetrahydro-3-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850033-72-6P, (3R,10BR)-1,3,4,10b-tetrahydro-3-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850033-73-7P, (3R,10BS)-1,3,4,10b-tetrahydro-3-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride
850033-76-0P 850033-79-3P 850033-81-7P
850033-82-8P 850033-83-9P 850033-85-1P
850033-87-3P 850034-21-8P 850034-23-0P,
1,3,4,10b-Tetrahydro-7-cyanopyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-25-2P 850034-26-3P
850034-29-6P 850034-38-7P 850034-40-1P,
(10bR)-1,3,4,10b-Tetrahydro-9-[(4-fluoro-3-methylphenyl)amino]-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850034-41-2P
850034-42-3P 850034-43-4P 850034-44-5P,
(10bR)-1,3,4,10b-Tetrahydro-9-[(2-fluoro-4-methoxyphenyl)amino]-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850034-45-6P
850034-46-7P, (10bR)-1,3,4,10b-Tetrahydro-9-[(4-fluoro-5-methyl-3-pyridinyl)amino]-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
850034-47-8P 850034-50-3P, (10bR)-1,3,4,10b-Tetrahydro-9-[(2-isopropoxy-5-methyl-3-pyridinyl)amino]-7-trifluoromethylpyrazino[2,1-

a]isoindol-6(2H)-one 850034-51-4P, (10bR)-1,3,4,10b-Tetrahydro-9-[(2-isopropoxy-4-methyl-3-pyridinyl)amino]-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850034-53-6P, (10bR)-1,3,4,10b-Tetrahydro-9-[(2-ethoxy-5-methyl-3-pyridinyl)amino]-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850034-54-7P, (4R,10bR)-1,3,4,10b-Tetrahydro-4-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-62-7P, (4R,10bS)-1,3,4,10b-Tetrahydro-4-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-63-8P, (4S,10bS)-1,3,4,10b-Tetrahydro-4-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-64-9P, (4S,10bR)-1,3,4,10b-Tetrahydro-4-methyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-65-0P, (4S,10bS)-1,3,4,10b-Tetrahydro-4-isopropyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-66-1P, (4S,10bR)-1,3,4,10b-Tetrahydro-4-isopropyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-67-2P, (4S,10bS)-1,3,4,10b-Tetrahydro-4-(2-methylpropyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-68-3P, (4S,10bR)-1,3,4,10b-Tetrahydro-4-(2-methylpropyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-69-4P, (4S,10bS)-1,3,4,10b-Tetrahydro-4-(phenylmethyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-70-7P, (4S,10bR)-1,3,4,10b-Tetrahydro-4-(phenylmethyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-71-8P 850034-73-0P 850034-74-1P 850034-77-4P 850034-79-6P, (10bR)-1,3,4,10b-Tetrahydro-9-(ethylthio)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-80-9P 850034-81-0P 850034-82-1P 850034-83-2P, (10bR)-1,3,4,10b-Tetrahydro-9-(pentan-3-yl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-85-4P 850034-86-5P, (10bR)-1,3,4,10b-Tetrahydro-9-cyclohexyl-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850034-88-7P 850034-89-8P 850034-90-1P 850034-92-3P 850034-93-4P 850034-95-6P 850034-97-8P 850034-99-0P 850035-00-6P 850035-01-7P 850035-04-0P 850035-07-3P, (R)-1,3,4,10b-Tetrahydro-9-(trans-1-propenyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850035-32-4P 850035-35-7P 850035-37-9P 850035-38-0P 850035-98-2P 850036-00-9P 850036-04-3P 850036-06-5P 850036-07-6P 850036-09-8P 850036-12-3P 850036-14-5P 850036-16-7P 850036-18-9P 850036-20-3P 850036-22-5P 850036-25-8P 850036-27-0P 850036-29-2P 850036-32-7P 850036-33-8P 850036-35-0P 850036-36-1P 850036-42-9P 850036-43-0P 850036-61-2P 850036-64-5P 850036-65-6P 850036-66-7P 850036-67-8P 850036-68-9P 850036-69-0P 850039-11-1P, (10bR)-1,3,4,10b-Tetrahydro-9-((1S,2R)-2-methylcyclopropyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850039-12-2P, (10bR)-1,3,4,10b-Tetrahydro-9-((1R,2S)-2-methylcyclopropyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850039-13-3P, (10bR)-1,3,4,10b-Tetrahydro-9-((1S,2S)-2-methylcyclopropyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850039-14-4P, (10bR)-1,3,4,10b-Tetrahydro-9-((1R,2R)-2-methylcyclopropyl)-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride 850040-46-9P, (10bS)-1,3,4,10b-Tetrahydro-7-cyclohexyl-9-ethylpyrazino[2,1-a]isoindol-6(2H)-one hydrochloride
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazino[2,1-a]isoindolone derivs. and related compds. as serotonin receptor modulators for treating metabolic diseases, central nervous system diseases, gastrointestinal disorders, etc.)

RN 850033-29-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-30-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-31-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-2-methyl-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850033-35-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-bromo-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-37-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[2-methyl-4-(trifluoromethoxy)phenyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-40-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(4-methoxy-2-methylphenyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-41-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[4-ethoxy-2-(trifluoromethyl)phenyl]-

1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-42-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(2,4-dichlorophenyl)-1,3,4,10b-
tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-43-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[2-methyl-4-
(methylthio)phenyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-44-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[2,4-bis(trifluoromethyl)phenyl]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-46-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-phenyl-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-45-3
CMF C18 H15 F3 N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-48-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(4-chlorophenyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-47-5
CMF C18 H14 Cl F3 N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-49-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[2-methyl-4-(methylsulfonyl)phenyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-51-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(2-chlorophenyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-52-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(3-chlorophenyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-59-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2,4-difluorophenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-58-8
CMF C18 H14 F5 N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-61-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(2-methoxyphenyl)amino]-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-60-2
CMF C19 H18 F3 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-63-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2,4-dimethoxyphenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-62-4
CMF C20 H20 F3 N3 O3

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-64-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(2-furanyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-66-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-3,3-dimethyl-7-(trifluoromethyl)- (9CI) (CA INDEX NAME)



RN 850033-69-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-3-methyl-7-(trifluoromethyl)-, monohydrochloride, (3S,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-70-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-3-methyl-7-(trifluoromethyl)-, monohydrochloride, (3S,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-72-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-3-methyl-7-(trifluoromethyl)-, monohydrochloride, (3R,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-73-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-3-methyl-7-(trifluoromethyl)-, monohydrochloride, (3R,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-76-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(phenylamino)-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-75-9
CMF C18 H16 F3 N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-79-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[[2-chloro-5-(trifluoromethyl)phenyl]amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-78-2
CMF C19 H14 Cl F6 N3 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-81-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[[4-(trifluoromethoxy)phenyl]amino]-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-80-6
CMF C19 H15 F6 N3 O2

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-82-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethenyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-83-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-acetyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850033-85-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 850033-84-0
CMF C14 H15 F3 N2 O

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2



RN 850033-87-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[4-(1-methylethoxy)-2-(trifluoromethyl)phenyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-21-8 CAPLUS
CN Pyrazino[2,1-a]isoindole-9-carbonitrile, 1,2,3,4,6,10b-hexahydro-6-oxo-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-23-0 CAPLUS
CN Pyrazino[2,1-a]isoindole-7-carbonitrile, 1,2,3,4,6,10b-hexahydro-6-oxo-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 850034-25-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(2-propenyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-26-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-propyl-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-29-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(1-propynyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-38-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2-ethoxyphenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-40-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(4-fluoro-3-methylphenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-41-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2,5-dichlorophenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-42-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2-fluorophenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-43-4 CAPLUS

CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2,3-difluorophenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-44-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2-fluoro-4-methoxyphenyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-45-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(2-methoxy-3-pyridinyl)amino]-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-46-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(4-fluoro-5-methyl-3-pyridinyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-47-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2-ethoxy-3-pyridinyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-50-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[[5-methyl-2-(1-methylethoxy)-3-pyridinyl]amino]-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-51-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[[4-methyl-2-(1-methylethoxy)-3-pyridinyl]amino]-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-53-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-[(2-ethoxy-5-methyl-3-pyridinyl)amino]-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-54-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-62-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4R,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-63-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4S,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-64-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-methyl-7-(trifluoromethyl)-, monohydrochloride, (4S,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-65-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-(1-methylethyl)-7-(trifluoromethyl)-, monohydrochloride, (4S,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-66-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-(1-methylethyl)-7-(trifluoromethyl)-, monohydrochloride, (4S,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-67-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-(2-methylpropyl)-7-(trifluoromethyl)-, monohydrochloride, (4S,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-68-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-(2-methylpropyl)-7-(trifluoromethyl)-, monohydrochloride, (4S,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-69-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-(phenylmethyl)-7-(trifluoromethyl)-, monohydrochloride, (4S,10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-70-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-4-(phenylmethyl)-7-(trifluoromethyl)-, monohydrochloride, (4S,10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-71-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(1Z)-1-propenyl-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 850034-73-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(2-methyl-1-propenyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-74-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(2-methylpropyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-77-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(methylthio)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-79-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(ethylthio)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-80-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(1-methylethyl)thio]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-81-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-butyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-82-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(1-cyclohexen-1-yl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-83-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(1-ethylpropyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-85-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-cyclopentyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-86-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-cyclohexyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-88-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(1-methylethyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-89-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-cyclopropyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-90-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(hydroxymethyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-92-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-methyl-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-93-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(methoxymethyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-95-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-hydroxy-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-97-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-methoxy-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850034-99-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethoxy-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-00-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(1-methylethoxy)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-01-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(cyclobutylmethoxy)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-04-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethynyl-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-07-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(1E)-1-propenyl-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



● HCl

RN 850035-32-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(2-methylcyclopropyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-35-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-(1-methylcyclopropyl)-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-37-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(difluoromethyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-38-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-(difluoromethyl)-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850035-98-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopropyl-9-ethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-00-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopropyl-9-ethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-04-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-methyl-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-06-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-methyl-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-07-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(1-methylethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-09-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(1-methylethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-12-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7,9-diethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-14-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7,9-diethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-16-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-propyl-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-18-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-propyl-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-20-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(2-methylpropyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-22-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(2-methylpropyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-25-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopentyl-9-ethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-27-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopentyl-9-ethyl-1,3,4,10b-tetrahydro-, (10bS)-, monohydrochloride, compd. with 2-methylpropane (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 850036-26-9
CMF C18 H24 N2 O

Absolute stereochemistry.



CM 2

CRN 75-28-5
CMF C4 H10



RN 850036-29-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclohexyl-9-ethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-32-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(hydroxymethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-33-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-ethyl-1,3,4,10b-tetrahydro-7-(hydroxymethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-35-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-chloro-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-36-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 9-chloro-1,3,4,10b-tetrahydro-7-(trifluoromethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-42-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-7,9-bis(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-43-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-7,9-bis(trifluoromethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-61-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-ethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-64-5 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopropyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-65-6 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopropyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-66-7 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopentyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-67-8 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclopentyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-68-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-10b-methyl-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850036-69-0 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-10b-methyl-7-(trifluoromethyl)-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850039-11-1 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(1S,2R)-2-methylcyclopropyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850039-12-2 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(1R,2S)-2-methylcyclopropyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850039-13-3 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(1S,2S)-2-

methylcyclopropyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850039-14-4 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 1,3,4,10b-tetrahydro-9-[(1R,2R)-2-methylcyclopropyl]-7-(trifluoromethyl)-, monohydrochloride, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 850040-46-9 CAPLUS
CN Pyrazino[2,1-a]isoindol-6(2H)-one, 7-cyclohexyl-9-ethyl-1,3,4,10b-tetrahydro-, monohydrochloride, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 850033-34-0 850033-86-2 850033-90-8
850033-96-4 850034-28-5 850034-76-3
850034-87-6 850035-03-9 850035-06-2,
2-(tert-Butoxycarbonyl)-(10bR)-1,3,4,10b-tetrahydro-9-
[(trimethylsilyl)ethynyl]-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-
one 850035-34-6 850035-36-8 850035-40-4,
2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-9-vinyl-7-
trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one 850036-34-9,
2-(tert-Butoxycarbonyl)-1,3,4,10b-tetrahydro-7-ethenyl-9-ethylpyrazino[2,1-
a]isoindol-6(2H)-one 850036-38-3, 2-(tert-Butoxycarbonyl)-
1,3,4,10b-tetrahydro-9-bromo-7-trifluoromethylpyrazino[2,1-a]isoindol-
6(2H)-one 850036-41-8, 2-(tert-Butoxycarbonyl)-1,3,4,10b-
tetrahydro-7-trifluoromethylpyrazino[2,1-a]isoindol-6(2H)-one
850036-63-4
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of pyrazino[2,1-a]isoindolone derivs. and related compds. as serotonin receptor modulators for treating metabolic diseases, central nervous system diseases, gastrointestinal disorders, etc.)

RN 850033-34-0 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-86-2 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-ethenyl-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-90-8 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850033-96-4 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-ethyl-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-28-5 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-9-(2-propenyl)-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-76-3 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(2-methyl-1-propenyl)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850034-87-6 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-(1-cyclohexen-1-yl)-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-03-9 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(1-methylethoxy)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-06-2 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-9-[(trimethylsilyl)ethynyl]-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-34-6 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-9-(1E)-1-propenyl-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 850035-36-8 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-9-(1-methylethenyl)-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester, (10bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 850035-40-4 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-ethenyl-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850036-34-9 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 7-ethenyl-9-ethyl-3,4,6,10b-tetrahydro-6-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850036-38-3 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 9-bromo-3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850036-41-8 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 3,4,6,10b-tetrahydro-6-oxo-7-(trifluoromethyl)-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 850036-63-4 CAPLUS
CN Pyrazino[2,1-a]isoindole-2(1H)-carboxylic acid, 7-ethenyl-3,4,6,10b-tetrahydro-6-oxo-, 1,1-dimethylethyl ester, (10bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 6 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:689336 CAPLUS
DOCUMENT NUMBER: 141:332093
TITLE: An efficient approach to isoindolo[2,1-b][2]benzazepines via intramolecular [4+2] cycloaddition of maleic anhydride to 4-α-furyl-4-N-benzylaminobut-1-enes
AUTHOR(S): Zubkov, Fedor I.; Boltukhina, Ekaterina V.; Turchin, Konstantin F.; Varlamov, Alexey V.
CORPORATE SOURCE: Organic Chemistry Department of Russian Peoples' Friendship University, Moscow, 117198, Russia
SOURCE: Tetrahedron (2004), 60(38), 8455-8463
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:332093
GI



I



II

AB Acylation of 4-α-furyl-4-N-benzylaminobut-1-enes, e.g., I, with maleic anhydride gave 4-oxo-3-aza-10-oxatricyclo[5.2.1.01,5]dec-8-ene-6-carboxylic acids by amide formation followed by intramol. Diels-Alder reaction of furan. The cycloaddn. proceeded under mild reaction conditions and provided only the exo-adducts in quant. yield. Treatment of these compds. with PPA gave isoindolo[2,1-b][2]benzazepines, e.g., II, by ring opening, aromatization and intramol. electrophilic alkylation. In order to extend the scope of the reaction sequence, II were further transformed into useful synthetic intermediates.

IT 773058-21-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of (morpholinylcarbonyl)dimethyldihydroisoindolobenzazepinone via chlorination of dimethyl(oxo)tetrahydroisoindolobenzazepinecarboxylic acid followed by amidation with morpholine)

RN 773058-21-2 CAPLUS

CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carbonyl chloride, 7,11b,12,13-tetrahydro-13,13-dimethyl-7-oxo- (9CI) (CA INDEX NAME)



IT 773058-22-3P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of (morpholinylcarbonyl)dimethyldihydroisoindolobenzazepinone via chlorination of dimethyl(oxo)tetrahydroisoindolobenzazepinecarboxylic acid followed by amidation with morpholine)

RN 773058-22-3 CAPLUS

CN Morpholine, 4-[(7,11b,12,13-tetrahydro-13,13-dimethyl-7-oxo-5H-isoindolo[2,1-b][2]benzazepin-8-yl)carbonyl]- (9CI) (CA INDEX NAME)



IT 773058-20-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of Me dimethyl(oxo)tetrahydroisoindolobenzazepinecarboxylate via esterification of dimethyl(oxo)tetrahydroisoindolobenzazepinecarboxylic acid)

RN 773058-20-1 CAPLUS

CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-13,13-dimethyl-7-oxo-, methyl ester (9CI) (CA INDEX NAME)



IT 773058-25-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of dimethyl(hydroxymethyl)tetrahydroisoindolobenzazepinone via reduction of dimethyl(oxo)tetrahydroisoindolobenzazepinecarboxylic acid)
RN 773058-25-6 CAPLUS
CN 7H-Isoindolo[2,1-b][2]benzazepin-7-one, 5,11b,12,13-tetrahydro-8-(hydroxymethyl)-13,13-dimethyl- (9CI) (CA INDEX NAME)



IT 773058-24-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of dimethyl(oxo)nitrotetrahydroisoindolobenzazepinecarboxylic acid via nitration of dimethyl(oxo)tetrahydroisoindolobenzazepinecarboxylic acid)
RN 773058-24-5 CAPLUS
CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-13,13-dimethyl-3-nitro-7-oxo- (9CI) (CA INDEX NAME)



IT 773058-14-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(stereoselective preparation of isoindolobenzazepinones via stereoselective [4 + 2]-cycloaddn. of N-benzyl[furanyl(methyl)butyl]amines with maleic anhydride followed by aromatization and stereoselective heterocyclization)
RN 773058-14-3 CAPLUS

CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-13,13-dimethyl-7-oxo-, (11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 773058-15-4P 773058-16-5P 773058-17-6P
773058-18-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(stereoselective preparation of isoindolobenzazepinones via stereoselective [4 + 2]-cycloaddn. of N-benzyl[furanyl(methyl)butyl]amines with maleic anhydride followed by aromatization and stereoselective heterocyclization)

RN 773058-15-4 CAPLUS
CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-9,13,13-trimethyl-7-oxo-, (11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773058-16-5 CAPLUS
CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-5,13,13-trimethyl-7-oxo-, (11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773058-17-6 CAPLUS
CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-2,13,13-trimethyl-7-oxo-, (11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 773058-18-7 CAPLUS
CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-2-methoxy-13,13-dimethyl-7-oxo-, (11bR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:387711 CAPLUS
DOCUMENT NUMBER: 141:295837
TITLE: Novel preparative method for synthesis of isoindolo[2,1-b]benz-2-azepine-8-carboxylic acids
AUTHOR(S): Zubkov, F. I.; Boltukhina, E. V.; Krapivko, A. P.; Varlamov, A. V.
CORPORATE SOURCE: Russian People's Friendship University, Moscow, 117198, Russia
SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2003), 39(11), 1534-1536
CODEN: CHCCAL; ISSN: 0009-3122
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 141:295837
GI



I

AB A procedure for preparation of isoindolo[2,1-b]benz-2-azepine-8-carboxylic acid (I) is reported. Maleic anhydride underwent [4 + 2]-cycloaddn. with a homoallylic amine followed by an acid-mediated heterocyclization to give I.

IT 496018-49-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of isoindolobenzazepinecarboxylic acid via [4 + 2]-cycloaddn. of N-(benzyl)methyl(furyl)butenylamine with maleic anhydride followed by heterocyclization)

RN 496018-49-6 CAPLUS

CN 5H-Isoindolo[2,1-b][2]benzazepine-8-carboxylic acid, 7,11b,12,13-tetrahydro-13,13-dimethyl-7-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:737759 CAPLUS
DOCUMENT NUMBER: 139:261291
TITLE: Preparation of condensed heterocyclic compounds such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivatives as calcitonin agonists
INVENTOR(S): Bhandari, Ashok; Boros, Eric Eugene; Cowan, David John; Handlon, Anthony Louis; Hyman, Clifton Earl; Oplinger, Jeffrey Alan; Rabinowitz, Michael Howard; Turnbull, Philip Stewart
PATENT ASSIGNEE(S): Smithkline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 174 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003076440	A1	20030918	WO 2003-US5605	20030224

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003213266	A1	20030922	AU 2003-213266		20030224
US 2005107419	A1	20050519	US 2003-507006		20030224
PRIORITY APPLN. INFO.:			US 2002-362011P	P	20020306
			WO 2003-US5605	W	20030224

OTHER SOURCE(S): MARPAT 139:261291
GI



I

AB The title compds. [I; R = each (un)substituted aryl, heteroaryl, alkyl, or cycloalkyl, further wherein said aryl, heteroaryl, alkyl, or cycloalkyl; Z = H, alkyl, halogen, CO2R5, CON(R5)2, CONHN(R5)2, NHCON(R5)2, SO2N(R5)2, CH2NHCOR5, NO2, N(R5)2, NHCOR5, N(R5)SO2N(R5)2, OR5, CH2N(R5)2, CH2CON(R5)2, CH2CO2R5, (un)substituted heteroaryl; R5 = independently H, alkyl, trifluoromethyl, each (un)substituted aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, heterocyclyl, fused cycloalkylaryl, or fused heterocyclylaryl; R1 = H, alkyl, CO2R5, COR5, CON(R5)2, cyano, NO2, N(R5)2, SO2R5, SO2N(R5)2, NHCOR5, NHCON(R5)2; R2 = alkyl, CF3, alkoxy, aryl, heteroaryl, aralkyl, heteroaralkyl, alkoxyaryl, further wherein said alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be substituted with one or more of halogen, CF3, or alkoxy; or R1 and R2 combine to form a 5- or 6-membered ring, optionally containing one or more heteroatom, optionally containing one or more degrees of unsatn., and optionally substituted one or more times with oxo, hydroxy, halogen, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, further wherein said alkyl, aryl, heteroaryl, aralkyl, and heteroaralkyl may be substituted with one or more of halogen, CF3, or alkoxy; A = C, N; Y = C, N; X = S, O, N(R5), C(R5)2, SO2; n = 1, 2, 3, or 4], salts, solvates, and pharmaceutically functional derivs. thereof are prepared These compds. are useful in the treatment and prevention of diseases or conditions which are related to irregular calcification or those mediated by calcitonin. They are used in therapies for osteopenia and osteoporosis in men and women; reduction in the risk of fractures, both vertebral and nonvertebral; Paget's disease; bone fracture or deficiency; primary or secondary hyperparathyroidism; periodontal disease or defect; metastatic bone disorder; osteolytic bone disease; post-plastic surgery; post-prosthetic joint surgery; postdental implantation; hypercalcemia; bone pain, general pain, and hyperalgesia; conditions associated with inhibiting gastric secretion; gastrointestinal disorders; osteoarthritis and rheumatoid arthritis; renal osteodystrophy; obesity by induction of satiety; and male infertility. Thus, 4-[3-(Ethoxycarbonyl)-2-[2-(4-fluorophenyl)ethyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1'2':1,2]pyrazolo[3,4-b]pyridin-4-yl]benzoic acid was condensed with furfurylamine using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and HOBT-H2O in DMF at room temperature for 4 h to give

2-[2-(4-fluorophenyl)ethyl]-4-[4-[[(2-furylmethyl)amino]carbonyl]phenyl]-5-oxo-8,9-dihydro-5H,7H-pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylate (II). In an CRE-luciferase reporter assay, II activated the human calcitonin-2 receptor (HCT2R) expressed in CHO-6CRE-luciferase cells with E50 of ≤10 nM.

IT 603999-03-7P 603999-05-9P 603999-07-1P
603999-11-7P 603999-16-2P 603999-20-8P
603999-22-0P 603999-28-6P 603999-32-2P
603999-37-7P 603999-49-1P 603999-51-5P
603999-65-1P 603999-67-3P 603999-69-5P
603999-78-6P 603999-80-0P 603999-82-2P
603999-98-0P 604000-00-2P 604000-04-6P
604000-16-0P 604000-30-8P 604000-32-0P
604000-45-5P 604000-47-7P 604000-59-1P
604000-67-1P 604000-69-3P 604000-71-7P
604000-75-1P 604000-77-3P 604000-89-7P
604001-01-6P 604001-05-0P 604001-07-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of condensed heterocyclic compds. such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivs. as calcitonin agonists for drugs)

RN 603999-03-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-05-9 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-07-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-aminophenyl)-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-11-7 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-(4-carboxyphenyl)-2-[2-(4-fluorophenyl)ethyl]-8,9-dihydro-5-oxo-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 603999-16-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxy-2-thienyl)-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-20-8 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxy-2-furanyl)-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-22-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(5-carboxy-2-thienyl)-2-

[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-28-6 CAPLUS
CN Benzoic acid, 4-[(9aS)-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-32-2 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[4-(ethoxycarbonyl)-2-oxazolyl]-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 603999-37-7 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-(4-carboxy-2-oxazolyl)-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, 3-ethyl ester (9CI) (CA INDEX NAME)



RN 603999-49-1 CAPLUS
CN Pyrazinecarboxylic acid, 5-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-51-5 CAPLUS
CN Pyrazinecarboxylic acid, 5-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-65-1 CAPLUS
CN Benzoic acid, 4-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-3-nitro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-67-3 CAPLUS
CN Benzoic acid, 4-[(9aS)-3-amino-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-69-5 CAPLUS
CN Benzoic acid, 4-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-3-[(trifluoroacetyl)amino]-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-78-6 CAPLUS
CN Benzoic acid, 4-[(9aS)-7,8,9,9a-tetrahydro-3-nitro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-80-0 CAPLUS
CN Benzoic acid, 4-[(9aS)-3-amino-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-82-2 CAPLUS
CN Benzamide, 4-[(9aS)-3-amino-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603999-98-0 CAPLUS
CN Benzoic acid, 4-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-3-(1-oxopropyl)-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-00-2 CAPLUS
CN Benzoic acid, 4-[(9aS)-2-ethyl-3-[3-(4-fluorophenyl)-1-oxopropyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-04-6 CAPLUS
CN Benzoic acid, 4-[(3aS)-6-(4-fluorophenyl)-2,3,3a,5,6,7,8,10-octahydro-8,10-dioxo-1H-pyrrolizino[1,2-b]quinolin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-16-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-7,8,9,9a-tetrahydro-5-oxo-2-[2-(3-pyridinyl)ethyl]-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-30-8 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-(carboxymethyl)phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-32-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, 3-ethyl ester, 1-oxide, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-45-5 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[6-(ethoxycarbonyl)-3-pyridazinyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-47-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(6-carboxy-3-pyridazinyl)-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-59-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-7,8,9,9a-tetrahydro-2-(4-methylpentyl)-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-67-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-7,8,9,9a-tetrahydro-5-oxo-2-(3,3,3-trifluoropropyl)-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-69-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-thienyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 604000-71-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-(aminomethyl)-2-thienyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-75-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[(1,3-dihydro-1,3-dioxo-2H-isoindol-2-yl)methyl]-2-thienyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 604000-77-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-(aminomethyl)-2-thienyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-89-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-7,8,9,9a-tetrahydro-5-oxo-2-(3-thienylmethyl)-, 3-ethyl ester, (9aS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604001-01-6 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxy-2-nitrophenyl)-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604001-05-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[3-carboxy-5-(trifluoromethyl)phenyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604001-07-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-carboxyphenyl)-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 603998-32-9P 603998-33-0P 603998-34-1P
603998-35-2P 603998-36-3P 603998-37-4P
603998-38-5P 603998-39-6P 603998-40-9P
603998-41-0P 603998-42-1P 603998-43-2P
603998-44-3P 603998-45-4P 603998-46-5P
603998-47-6P 603998-48-7P 603998-49-8P
603998-50-1P 603998-51-2P 603998-52-3P
603998-53-4P 603998-54-5P 603998-55-6P
603998-56-7P 603998-57-8P 603998-58-9P
603998-59-0P 603998-60-3P 603998-61-4P
603998-62-5P 603998-63-6P 603998-64-7P
603998-65-8P 603998-66-9P 603998-67-0P
603998-68-1P 603998-69-2P 603998-70-5P
603998-71-6P 603998-72-7P 603998-73-8P
603998-74-9P 603998-75-0P 603998-76-1P
603998-77-2P 603998-78-3P 603998-79-4P
603998-80-7P 603998-81-8P 603998-82-9P
603998-83-0P 603998-84-1P 603998-85-2P
603998-86-3P 603998-87-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of condensed heterocyclic compds. such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivs. as calcitonin agonists for drugs)

RN 603998-32-9 CAPLUS

CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-2-[2-(4-methoxyphenyl)ethyl]-5-oxo-, ethyl ester, (9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-33-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]sulfonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-34-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-5-oxo-4-[2-[[(phenylmethyl)amino]carbonyl]cyclopropyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-35-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-5-oxo-4-[4-[[[(1R)-1-(4-pyridinyl)ethyl]amino]carbonyl]phenyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-36-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-5-oxo-4-[4-[[[(1S)-1-(4-pyridinyl)ethyl]amino]carbonyl]phenyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-37-4 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[(2,4-difluorophenyl)methyl]-4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 603998-38-5 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-5-oxo-4-[4-[[(phenylamino)carbonyl]amino]phenyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-39-6 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 603998-40-9 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-4-[5-[[(2-furanylmethyl)amino]carbonyl]-2-thienyl]-8,9-dihydro-5-oxo-, ethyl ester (9CI) (CA INDEX NAME)



RN 603998-41-0 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[4-[[[(3-fluorophenyl)methyl]amino]carbonyl]phenyl]-8,9-dihydro-5-oxo-2-(trifluoromethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 603998-42-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-43-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-5-oxo-4-[5-[[(3-pyridinylmethyl)amino]carbonyl]-2-furanyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-44-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[3-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-45-4 CAPLUS
CN Benzamide, N-(2-furanylmethyl)-4-[(9aS)-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-46-5 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-47-6 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(3,4-difluorophenyl)methyl]amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-48-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]-2-furanyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-49-8 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-thienyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-50-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-thiazolyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-51-2 CAPLUS
CN Benzamide, N-[(1R)-2,3-dihydro-1H-inden-1-yl]-4-[(9aS)-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-52-3 CAPLUS
CN 5H,7H-Pyrazolo[1',2':1,2]pyrazolo[3,4-b]pyridine-3-carboxylic acid, 4-[5-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-oxazolyl]-8,9-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-53-4 CAPLUS
CN Pyrazinecarboxamide, 5-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-[(1R)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-54-5 CAPLUS
CN Benzamide, 4-[(9aS)-2-[(2,4-difluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-3-[(trifluoroacetyl)amino]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-[(1R)-2,3-dihydro-1H-inden-1-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-55-6 CAPLUS
CN Benzamide, 4-[(9aS)-3-[(cyclopentylcarbonyl)amino]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-56-7 CAPLUS
CN Benzamide, N-(2-furanylmethyl)-4-[(9aS)-7,8,9,9a-tetrahydro-5-oxo-3-[(1-oxopropyl)amino]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-57-8 CAPLUS
CN Benzamide, 4-[(9aS)-3-[(cyclopropylcarbonyl)amino]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-58-9 CAPLUS
CN Benzamide, N-(2-furanylmethyl)-4-[(9aS)-7,8,9,9a-tetrahydro-5-oxo-3-[(trifluoroacetyl)amino]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-59-0 CAPLUS
CN Benzamide, 4-[(9aS)-3-cyano-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-60-3 CAPLUS
CN Benzamide, 4-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-3-(1-oxopropyl)-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-61-4 CAPLUS
CN Benzamide, 4-[(9aS)-2-ethyl-3-[3-(4-fluorophenyl)-1-oxopropyl]-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-62-5 CAPLUS
CN Benzamide, 4-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-3-(2-furanylcarbonyl)-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]-N-(2-furanylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-63-6 CAPLUS
CN Benzamide, N-[(1R)-2,3-dihydro-1H-inden-1-yl]-4-[(3aS)-6-(4-fluorophenyl)-2,3,3a,5,6,7,8,10-octahydro-8,10-dioxo-1H-pyrrolizino[1,2-b]quinolin-9-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-64-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-(3-pyridinyl)ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-65-8 CAPLUS
CN 5H,7H-Thiazolo[3',4':1,2]pyrrolo[3,4-b]pyridine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-9,9a-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-66-9 CAPLUS
CN 5H,7H-Thiazolo[3',4':1,2]pyrrolo[3,4-b]pyridine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-9,9a-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, 8,8-dioxide, (9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-67-0 CAPLUS
CN 5H,7H-Oxazolo[3',4':1,2]pyrrolo[3,4-b]pyridine-3-carboxylic acid, 9,9a-dihydro-5-oxo-4-[4-[[(phenylmethyl)amino]carbonyl]phenyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-68-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[2-[(2-furanylmethyl)amino]-2-oxoethyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-69-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, 1-oxide, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-70-5 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[(4-fluorophenyl)methyl]-4-[6-[[(2-furanylmethyl)amino]carbonyl]-3-pyridazinyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 603998-71-6 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-4-(4-methylphenyl)-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-72-7 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-4-[4-[[[3-(1H-imidazol-1-yl)propyl]amino]carbonyl]phenyl]-5-oxo-2-[2-[4-

(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-73-8 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-4-[4-[[[2-(1H-imidazol-4-yl)ethyl]amino]carbonyl]phenyl]-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-74-9 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-2-(4-methylpentyl)-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-75-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(3,3,3-trifluoropropyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-76-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[(2,4-difluorophenyl)methyl]-4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-77-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[5-[(benzoylamino)methyl]-2-thienyl]-2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-78-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 7,8,9,9a-tetrahydro-5-oxo-4-[5-[[(3-pyridinylcarbonyl)amino]methyl]-2-thienyl]-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-79-4 CAPLUS
CN 1H-Pyrrolo[2,1-a]isoindole-7-carboxylic acid, 8-[2-(4-fluorophenyl)ethyl]-2,3,5,9b-tetrahydro-5-oxo-6-[4-[(phenylmethoxy)carbonyl]phenyl]-, ethyl ester, (9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-80-7 CAPLUS
CN 1H-Pyrrolo[2,1-a]isoindole-7-carboxylic acid, 6-(4-carboxyphenyl)-8-[2-(4-fluorophenyl)ethyl]-2,3,5,9b-tetrahydro-5-oxo-, 7-ethyl ester, (9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-81-8 CAPLUS
CN 1H-Pyrrolo[2,1-a]isoindole-7-carboxylic acid, 8-[2-(4-fluorophenyl)ethyl]-6-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-2,3,5,9b-tetrahydro-5-oxo-, ethyl ester, (9bS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-82-9 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2-furanylmethyl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(3-thienylmethyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-83-0 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[2-(4-fluorophenyl)ethyl]-4-[3-fluoro-4-[[[(1S)-1-(4-pyridinyl)ethyl]amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-84-1 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[[(1R)-2,3-dihydro-1H-inden-1-yl]amino]carbonyl]-2-nitrophenyl]-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-85-2 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 2-[(4-fluorophenyl)methyl]-7,8,9,9a-tetrahydro-5-oxo-4-[3-[[[2-(2-thienyl)ethyl]amino]carbonyl]-5-(trifluoromethyl)phenyl]-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





RN 603998-86-3 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-[4-[[(2,3-dihydro-1H-inden-1-yl)amino]carbonyl]phenyl]-7,8,9,9a-tetrahydro-5-oxo-2-(phenylmethyl)-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 603998-87-4 CAPLUS
CN 5H-Pyrido[2,3-a]pyrrolizine-3-carboxylic acid, 4-(4-bromo-2-thienyl)-2-[2-(4-fluorophenyl)ethyl]-7,8,9,9a-tetrahydro-5-oxo-, ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 604000-02-4 604000-24-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(reactant; preparation of condensed heterocyclic compds. such as 5-oxo-7,8,9,9a-tetrahydro-5H-pyrido[2,3-a]pyrrolizine derivs. as

calcitonin agonists for drugs)
RN 604000-02-4 CAPLUS
CN Benzoic acid, 4-[(9aS)-2-[2-(4-fluorophenyl)ethyl]-3-(2-furanylcarbonyl)-7,8,9,9a-tetrahydro-5-oxo-5H-pyrido[2,3-a]pyrrolizin-4-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 604000-24-0 CAPLUS
CN 5H,7H-Oxazolo[3',4':1,2]pyrrolo[3,4-b]pyridine-3-carboxylic acid, 4-(4-carboxyphenyl)-9,9a-dihydro-5-oxo-2-[2-[4-(trifluoromethyl)phenyl]ethyl]-, 3-ethyl ester, (9aS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2003:293541 CAPLUS
DOCUMENT NUMBER: 139:214349
TITLE: A general strategy for the synthesis of oxoisoindolo[2,1-a]quinoline derivatives. The first

	efficient synthesis of 5,6,6a,11-tetrahydro-11-oxoisoindolo[2,1-a]quinoline-10-carboxylic acids
AUTHOR(S):	Varlamov, Alexey V.; Zubkov, Fedor I.; Boltukhina, Ekaterina V.; Sidorenko, Natalya V.; Borisov, Roman S.
CORPORATE SOURCE:	Organic Chemistry Department, Russian Peoples Friendship University, Moscow, 117198, Russia
SOURCE:	Tetrahedron Letters (2003), 44(18), 3641-3643 CODEN: TELEAY; ISSN: 0040-4039
PUBLISHER:	Elsevier Science Ltd.
DOCUMENT TYPE:	Journal
LANGUAGE:	English
OTHER SOURCE(S):	CASREACT 139:214349

GI



I

AB An efficient two-step synthesis of new isoindolo[2,1-a]quinoline-10-carboxylic acids I (R = H, 1-Me, 1-Bn, 1-MeO, 3-Et, 3-MeO, 3-F) via [4+2] cycloaddn. of the 4-α-furyl-4-N-arylaminobut-1-enes and maleic anhydride is described.

IT 433974-44-8P 496018-43-0P 496018-44-1P
588706-12-1P 588706-13-2P 588706-14-3P
588706-15-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of 5,6,6a,11-tetrahydro-11-oxoisoindolo[2,1-a]quinoline-10-carboxylic acids via [4+2] cycloaddn. reaction of 4-α-furyl-4-N-arylaminobut-1-enes with maleic anhydride)

RN 433974-44-8 CAPLUS

CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1-methoxy-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 496018-43-0 CAPLUS

CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 496018-44-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-fluoro-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 588706-12-1 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-1,5,5-trimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 588706-13-2 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo-1-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 588706-14-3 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 3-ethyl-5,6,6a,11-tetrahydro-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



RN 588706-15-4 CAPLUS
CN Isoindolo[2,1-a]quinoline-10-carboxylic acid, 5,6,6a,11-tetrahydro-3-methoxy-5,5-dimethyl-11-oxo- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 10 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 1999:48723 CAPLUS
DOCUMENT NUMBER: 130:125086
TITLE: Preparation of spiro[pyridoisoindolequinazoline] derivatives and analogs as nitric oxide synthase inhibitors
INVENTOR(S): Hamley, Peter; Pimm, Austen; Tinker, Alan
PATENT ASSIGNEE(S): Astra Pharmaceuticals Ltd., UK; Astra Aktiebolag
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9901455	A1	19990114	WO 1998-SE1206	19980622
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ZA 9805326	A	19990323	ZA 1998-5326	19980618
CA 2294734	AA	19990114	CA 1998-2294734	19980622
AU 9881356	A1	19990125	AU 1998-81356	19980622
AU 729792	B2	20010208		
EP 1000064	A1	20000517	EP 1998-931170	19980622
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
TR 9903296	T2	20000721	TR 1999-3296	19980622
BR 9810214	A	20000808	BR 1998-10214	19980622

EE 9900602	A	20000815	EE 1999-602		19980622
JP 2002507987	T2	20020312	JP 1999-507006		19980622
US 6083952	A	20000704	US 1998-125174		19980811
MX 9911983	A	20000430	MX 1999-11983		19991217
NO 9906544	A	20000229	NO 1999-6544		19991229
US 6211189	B1	20010403	US 2000-583775		20000531
PRIORITY APPLN. INFO.:			SE 1997-2534	A	19970701
			WO 1998-SE1206	W	19980622
			US 1998-125174	A3	19980811

OTHER SOURCE(S): MARPAT 130:125086

GI



I



II

AB There are provided novel compds. I [wherein A = atoms to complete aromatic carbocyclic ring or 5- or 6-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms which may be the same or different and are selected from O, N and S; X = (CH2)n where n = 0 or 1; R1 and R2 = H, alk(en/yn)yl, alkoxy, alkylthio, halo, OH, CF3, or amino; R3 = one or more substituents selected from H, alk(en/yn)yl, alkoxy, alkylthio, halo, OH, CF3, amino, cyano, nitro, CF3O, MeSO2, SO2NH2, NR4R5, COOR6, CONR7R8, PhCH2O, Ph, or an (un)substituted 5-membered heterocyclic aromatic ring containing 1 to 3 heteroatoms; R4, R5, R6 = H, alkyl; R7, R8 = H, alkyl, (un)substituted Ph] and their pharmaceutically acceptable salts, enantiomers, and tautomers, together with processes for their preparation, compns. containing them, and their use in therapy. The compds. are inhibitors of nitric oxide synthase (NOS), and are thereby particularly useful in the treatment or prophylaxis of inflammatory disease and pain. Approx. 30 examples of I, as free bases and/or salts, were prepared and/or claimed, and showed IC50 values < 25 μM in two screening assays for inhibition of NOS. For instance, cyclocondensation of 2-amino-6-fluorobenzamidine with 1,3,4,10a-tetrahydropyrido[2,1-a]isoindole-2,6-dione in refluxing EtOH, followed by flash column chromatog., gave 2 racemic diastereomers of title compound II.

IT 219843-22-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of spiro[pyridoisoindolequinazoline] derivs. as nitric oxide synthase inhibitors)

RN 219843-22-8 CAPLUS

CN Pyrido[2,1-a]isoindole-2,6-dione, 1,3,4,10b-tetrahydro-7-methyl- (9CI) (CA INDEX NAME)



IT 219842-66-7P 219842-67-8P 219842-91-8P
219842-92-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(target compound; preparation of spiro[pyridoisoindolequinazoline] derivs. as
nitric oxide synthase inhibitors)

RN 219842-66-7 CAPLUS
CN Spiro[pyrido[2,1-a]isoindole-2(6H),2'(1'H)-quinazolin]-6-one, 4'-amino-5'-fluoro-1,3,4,10b-tetrahydro-7-methyl-, monohydrochloride, (2R,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 219842-67-8 CAPLUS
CN Spiro[pyrido[2,1-a]isoindole-2(6H),2'(1'H)-quinazolin]-6-one, 4'-amino-5'-fluoro-1,3,4,10b-tetrahydro-7-methyl-, monohydrochloride, (2R,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



● HCl

RN 219842-91-8 CAPLUS
CN Spiro[pyrido[2,1-a]isoindole-2(6H),2'(1'H)-quinazolin]-6-one, 4'-amino-5'-fluoro-1,3,4,10b-tetrahydro-7-methyl-, (2R,10bR)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 219842-92-9 CAPLUS
CN Spiro[pyrido[2,1-a]isoindole-2(6H),2'(1'H)-quinazolin]-6-one, 4'-amino-5'-fluoro-1,3,4,10b-tetrahydro-7-methyl-, (2R,10bS)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 14:42:15 ON 06 JUL 2006)

FILE 'REGISTRY' ENTERED AT 14:42:35 ON 06 JUL 2006
L1 STRUCTURE UPLOADED
L2 432 S L1 FULL

FILE 'CAPLUS' ENTERED AT 14:43:35 ON 06 JUL 2006
L3 10 S L2 FULL

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	51.56	219.15
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-7.50	-7.50

STN INTERNATIONAL LOGOFF AT 14:44:23 ON 06 JUL 2006